Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.09T
24h Vol:
$8.59B
Dominance:
MSFT:4.90%
Stocklytics Platform
Asset logo for symbol TXG
10X Genomics
TXG
62
$20.25arrow_drop_up2.68%$0.53

Performance History

Chart placeholder
Key Stats
Open$19.61
Prev. Close$19.72
EPS-2.24
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$2.67B
PE Ratio-
LOWHIGH
Day Range19.34
20.29
52 Week Range19.34
63.57
Ratios
P/B Ratio5.56
Revenue$618.72M
Operating M. %-42.12%
Earnings$0.00
Earnings Growth %-53.67%
EBITDA Margin %-26.53%
ROE %-34.75%
EPS-2.24

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

info
There's no data available for Analyst Forecast

Analyst Ratings

info
There's no data available for Analyst Ratings

Correlated Companies

PRICE$878.45
24H (%)arrow_drop_down0.55%
24H ($)-$4.88
MARKET CAP$771.28B
PRICE$497.12
24H (%)arrow_drop_down0.03%
24H ($)-$0.17
MARKET CAP$443.63B
PRICE$145.53
24H (%)arrow_drop_up0.06%
24H ($)$0.09
MARKET CAP$347.62B
PRICE$129.48
24H (%)arrow_drop_up0.08%
24H ($)$0.11
MARKET CAP$318.88B

About 10X Genomics (TXG)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Sector
Healthcare
Industry
Health Information Services
CEO
Dr. Serge Saxonov Ph.D.
Headquarters
Pleasanton
Employees
1243
Exchange
NASDAQ
add 10X Genomics  to watchlist

Keep an eye on 10X Genomics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is 10X Genomics 's (TXG) price per share?

The current price per share for 10X Genomics (TXG) is $20.25. The stock has seen a price change of $0.53 recently, indicating a 2.69% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for 10X Genomics (TXG)?

For 10X Genomics (TXG), the 52-week high is $63.57, which is 213.93% from the current price. The 52-week low is $19.34, the current price is 4.71% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is 10X Genomics (TXG) a growth stock?

10X Genomics (TXG) has shown an average price growth of 0.41% over the past three years. It has received a score of 11 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying 10X Genomics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is 10X Genomics (TXG) stock price performance year to date (YTD)?

As of the latest data, 10X Genomics (TXG) has a year-to-date price change of -62.71%. Over the past month, the stock has experienced a price change of -23.27%. Over the last three months, the change has been -44.26%. Over the past six months, the figure is -62.13%.

help
Is 10X Genomics (TXG) a profitable company?

10X Genomics (TXG) has a net income of -$255.1M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 66.15% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -42.12% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $618.73M, with a revenue growth rate of 19.81%, providing insight into the company's sales performance and growth. The gross profit is $409.31M. Operating income is noted at -$201.87M. Furthermore, the EBITDA is -$164.14M.

help
What is the market capitalization of 10X Genomics (TXG)?

10X Genomics (TXG) has a market capitalization of $2.67B. The average daily trading volume is 1.17M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level